Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib

Table 5 Univariate analysis of factors associated with overall survival in 44 patients with hepatocellular carcinoma and cirrhosis treated with sorafenib

Variable	n	Overall survival
		HR (95%CI)	P value
Gender
Male	38	1 (ref.)	0.437
Female	6	1.52(0.53-4.38)
ECOG
0	24	1 (ref.)	0.049
1-2	20	2.01(1.01-4.05)
Age, yr
< 70	22	1 (ref.)	0.297
≥ 70	22	1.43 (0.73-2.78)
Cirrhosis etiology
Non-viral	12	1 (ref.)	0.832
HCV or HBV1	32	1.09 (0.51-2.34)
Extrahepatic spread
Absent	35	1 (ref.)	0.049
Present	9	2.26 (1.01-5.10)
Portal thrombosis
Absent	36	1 (ref.)	0.043
Present	8	2.52 (1.03-6.16)
HBV infection
Absent	32	1 (ref.)	0.279
Present	12	0.64 (0.29-1.43)
HCV infection
Absent	23	1 (ref.)	0.423
Present	21	1.32 (0.67-2.57)
Esophageal varices
Absent	28	1 (ref.)	0.883
Present	16	1.06 (0.52-2.14)
Child Pugh score
A	29	1 (ref.)	0.085
B	15	1.98 (0.91-4.29)
BCLC class
B	15	1 (ref.)	0.007
C	29	2.89 (1.34-6.25)
Previous therapy
No	19	1 (ref.)	0.526
Yes	25	1.25 (0.63-2.49)
Bilirubin (mg/dL)
≤ 1.5	27	1 (ref.)	0.124
>1.5	17	1.76 (0.86-3.60)
gGT (U/L)
≤ 48	5	1 (ref.)	0.483
> 48	39	1.54 (0.46-5.14)
ALP (U/L)
≤ 120	13	1 (ref.)	0.013
>120	31	3.20 (1.28-7.98)
Platelets/mm3
≤ 150000	28	1 (ref.)	0.317
> 150000	16	0.69 (0.33-1.43)
AST (U/L)
≤ 40	9	1 (ref.)	0.388
> 40	35	1.52 (0.59-3.94)
AFP (ng/mL)
≤ 40	22	1 (ref.)	0.016
> 40	22	2.38 (1.18-4.80)
AFP (ng/mL)
≤ 400	27	1 (ref.)	0.017
> 400	17	2.38 (1.17-4.86)
Interruption due to disease progression
No	19	1 (ref.)	0.238
Yes	25	0.67 (0.34 - 1.31)

¹Including patients with other concurrent etiologies. gGT: Gamma-glutamyltranspeptidase; ALP: Alkaline phosphatase; AST: Aspartate transaminase; AFP: Alpha-fetoprotein; HCV: Hepatitis C virus; HBV: Hepatitis B virus; ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona clinic liver cancer.